Reuters logo
BRIEF-Vascular Biogenics presents positive mid-stage data in brain cancer patients
June 5, 2017 / 11:52 AM / 6 months ago

BRIEF-Vascular Biogenics presents positive mid-stage data in brain cancer patients

June 5 (Reuters) - Vascular Biogenics Ltd

* Vascular biogenics-new data showing treatment with vb-111 induced durable tumor regression,attenuation of tumor growth in patients with recurrent glioblastoma​

* Vascular biogenics ltd - ‍first cohort behaved like an avastin historical control with a median overall survival (mos) of 8 months​

* Vascular biogenics ltd - ‍second cohort received in median 4 doses of vb-111, about 8 months of treatment​

* Vascular biogenics ltd - expects interim analysis of globe trial to occur in q3 2017, with top-line results from full dataset expected in early 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below